ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 18.71% | 22.45% | -50.28% | -32.93% | -66.68% |
| Total Depreciation and Amortization | -1.82% | -6.09% | 41.89% | 22.97% | -3.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.44% | -28.85% | 99.25% | 53.98% | 140.30% |
| Change in Net Operating Assets | 133.40% | 130.20% | 190.30% | -232.97% | -391.82% |
| Cash from Operations | 49.80% | 44.70% | 55.66% | -39.30% | -125.72% |
| Capital Expenditure | 95.53% | 83.59% | 34.19% | 37.35% | 54.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -100.00% | -100.00% | 15,622.03% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 710.84% | 3,399.57% | -- | -- | -- |
| Cash from Investing | -63.38% | -55.50% | -100.28% | -100.82% | 901.43% |
| Total Debt Issued | -60.36% | -73.17% | -97.03% | -98.45% | 91.26% |
| Total Debt Repaid | 34.82% | 25.92% | 14.53% | 63.18% | -1,178.43% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -47.40% | -66.42% | -96.74% | -104.09% | 49.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -437.66% | -155.90% | -196.71% | -196.06% | -84.73% |